Merck and Ridgeback Biotherapeutics received authorization in the UK for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 test and who have at least one risk factor for developing severe illness.   In the UK, LAGEVRIO (lah-GEV-ree-oh) is the planned trademark for molnupiravir. Merck’s application with the U.S. FDA for Emergency Use Authorization of molnupiravir is under review and...